[1]
R. Schreiber, C. Lewis, and K. Crane, “Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance”, J of Skin, vol. 2, p. S57, Dec. 2018.